Sprycel
utilized to target kinase-positive leukaemias and formulated to support the mitigation of malignant cell growth in patients.
Strengths: 50mg
Where to Check Availability
Medicine details
- Therapeutic class
Tyrosine Kinase Inhibitor
- Pharmacological class
BCR-ABL Kinase Inhibitor
- Contraindications
hypersensitivity to dasatinib
- Minor side effects
diarrhoea; nausea; headache; fatigue
- Moderate side effects
pleural effusion; haemorrhage; anaemia
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
variable
- Duration
continuous
- Storage instructions
Store at room temperature in original packaging.
- Drug interactions
proton pump inhibitors; h2 antagonists
- Age restrictions
Not recommended for children under 1 year.
Precautions and warnings
monitor for fluid retention; avoid strenuous activity if bleeding occurs; frequent monitoring of full blood count
Serious side effects
severe pulmonary hypertension — requires immediate medical attention; haemorrhage — requires immediate medical attention
Patient summary
utilized to target kinase-positive leukaemias and formulated to support the mitigation of malignant cell growth in patients.
Mechanism of action
Dasatinib is a multi-targeted kinase inhibitor that targets BCR-ABL, SRC family kinases, and other kinases to block the growth of Philadelphia chromosome-positive leukemic cells.
Pregnancy and breastfeeding
Pregnancy: Avoid conception; suspected foetal harm. Breastfeeding: Not recommended.
Sprycel
utilized to target kinase-positive leukaemias and formulated to support the mitigation of malignant cell growth in patients.
Editorial Notes
- Active ingredient(s): Dasatinib
- Listed indication(s): Chronic Myeloid Leukaemia, Acute Lymphoblastic Leukaemia
Available option
- 1 bottle - 50 mg1040-50-mg-13091